The purpose of this study was to determine the association of socioeconomic factors on use of cardioprotective medicines in known coronary heart disease (CHD) or stroke in South Asia.
Methods
We enrolled 33,423 subjects aged 35–70 years (women 56%, rural 53%, low education 51%, low household wealth 25%) in 150 communities in India, Pakistan and Bangladesh during 2003–2009. Information regarding socioeconomic status, disease conditions and treatments was recorded. We studied influence of rural location, educational status and household wealth on use of drug therapies. Odds ratios (ORs) and 95% confidence intervals were calculated.
Results
CHD was reported in 683 (2.0%), stroke 316 (0.9%), and CHD/stroke in 970 (2.9%). Median duration since diagnosis was four years. Participants with CHD/stroke were older with greater prevalence of smoking, overweight, hypertension and diabetes (p < 0.01). In patients with CHD, stroke and CHD/stroke, respectively, use (%) of antiplatelets was 11.6, 3.8 and 9.3, beta-blockers 11.9, 7.0 and 10.4, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers 6.4, 1.9 and 5.3 and statins 4.8, 0.6 and 3.5. In CHD/stroke patients any one of these drugs was used in 18.1%, any two in 7.2%, any three in 2.8% and none in 81.5%. Details of drug dose were not available. Use of drugs was significantly lower in rural low education and low wealth index participants (all p < 0.01). Low wealth index participants had the lowest use of these therapies with no attenuation after multiple adjustments.
Conclusion
The use of secondary preventive drug therapies in patients with known CHD or stroke in South Asia is low with over 80% receiving none of the effective drug treatments. Low household wealth is the most important determinant.
World Health Organization. Global status report on noncommunicable diseases 2010, Geneva: World Health Organization, 2011, pp. 100–107.
2.
LeonDAWaltG. Poverty, inequality and health: An international perspective, Oxford: Oxford University Press, 2001, pp. 1–123.
3.
BerkmanLFKawachiI. Social epidemiology, New York: Oxford University Press, 2000, pp. 13–94.
4.
MarmotM. The status syndrome: How social standing affects our health and longevity, New York: Henry Holt and Company, 2004, pp. 13–137.
5.
StansfeldSAMarmotM. Stress and the heart: Psychosocial pathways to coronary heart disease, London: BMJ Books, 2002, pp. 86–199.
6.
Beaglehole R, Bonita R, Hoton R, et al.; Lancet NCD Action Group. Priority actions for the noncommunicable disease crisis. Lancet 2011; 377: 1438–1447.
7.
Di Cesare M, Khang Y-H, Asaria P, et al.; Lancet NCD Action Group. Inequalities in non-communicable diseases and effective responses. Lancet 2013; 381: 585–597.
8.
SmithSCBenjaminEJBonowRO. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. J Am Coll Cardiol2011; 58: 2432–2446.
9.
YusufS. Two decades of progress in preventing vascular disease. Lancet2002; 360: 2–3.
10.
EUROASPIRE Study Group. EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease, principal results. Eur Heart J1997; 18: 1569–1582.
11.
WoodDA. for the EUROASPIRE Group. Clinical realities of coronary prevention: Comparison of EUROASPIRE I and II in nine countries. Lancet2001; 357: 995–1001.
12.
Kotseva K, Wood D, De Backer G, et al.; EUROASPIRE Study Group. EUROASPIRE III: A survey on lifestyles, risk factors and use of cardioprotective therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehab 2009; 16: 121–137.
13.
MendisSAbegundeDYusufS. WHO study in prevention and recurrence of myocardial infarction and stroke (WHO PREMISE). Bull WHO2005; 83: 820–828.
14.
SharmaKKGuptaRAgrawalA. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India. Vasc Health Risk Manag2009; 5: 1007–1014.
15.
JoshiRChowCKRajuPK. Fatal and nonfatal cardiovascular disease and the use of therapies for secondary prevention in a rural region of India. Circulation2009; 119: 1950–1955.
16.
ArifHAijazBIslamM. Drug compliance after stroke and myocardial infarction: A comparative study. Neurol India2007; 55: 130–135.
17.
BleichSNKoehlmoosTLRashidM. Noncommunicable chronic disease in Bangladesh: Overview of existing programs and priorities going forward. Health Policy2011; 100: 282–289.
18.
BeagleholeREpping-JordanAPatelV. Improving the prevention and management of chronic diseases in low-income and middle-income countries: A priority for primary health care. Lancet2008; 372: 940–949.
19.
YusufSIslamSChowCK. and Prospective Urban Rural Epidemiology (PURE) Study Investigators. Low use of secondary prevention medications for cardiovascular disease in the community in 17 high, middle and low income countries (The PURE Study). Lancet2011; 378: 1231–1243.
20.
TeoKKLearSIslamS. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. JAMA2013; 309: 1613–1619.
21.
CorsiDSubramanianSVChowCK. The Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries. Am Heart J2013; 166: 636–646.
22.
BhattDLStegGOhmanM. for the REACH Registry Investigators. International prevalence, recognition and treatment, of cardiovascular risk factors in outpatients with atherothrombosis. JAMA2006; 295: 180–189.
23.
ChanPSOetgenWJBuchananDJ. Cardiac performance measures in outpatients: The American College of Cardiology National Cardiovascular Data Registry’s PINNACLE (Practice Innovation and Clinical Excellence) program. J Am Coll Cardiol2010; 56: 8–14.
24.
StegPGFerrariRFordI. for the CLARIFY Investigators. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One2012; 7: e36284–e36284.
25.
QuereshiAISuriMFGutermanLRHopkinsLN. Ineffective secondary prevention in survivors of cardiovascular events in US population: Report from the Third National Health and Nutrition Examination Survey. Arch Intern Med2001; 161: 1621–1628.
26.
MuntnerPDeSalvoKBWildmanRP. Trends in the prevalence, awareness, treatment and control of cardiovascular disease risk factors among non-institutionalised patients with a history of myocardial infarction and stroke. Am J Epidemiol2006; 163: 913–920.
27.
ShahNSHuffmanMDNingH. Trends in vascular risk factor treatment and control in US stroke survivors: The National Health and Nutrition Examination Surveys (1999–2010). Circ Cardiovasc Outcomes2013; 6: 270–277.
28.
NagpalJBhartiaA. Quality of diabetes care in the middle- and high-income group populace: The Delhi Diabetes Community (DEDICOM) survey. Diabetes Care2006; 29: 2341–2348.
29.
OsterbergLBlaschkeT. Adherence to medication. N Engl J Med2005; 353: 487–497.
30.
KarthikeyanGXavierDPrabhakaranD. Perspectives on the management of coronary artery disease in India. Heart2007; 93: 1334–1338.
31.
NaderiSHBestwickJPWaldDS. Adherence to drugs that prevent cardiovascular disease: Meta-analysis on 376,162 patients. Am J Med2012; 125: 882–887.
32.
BanerjeeAVDufloE. Poor economics: Rethinking poverty and the ways to end it, London: Random House, 2011, pp. 61–71.
33.
SachsJ. The end of poverty: How we can make it happen in our lifetime, London: Penguin Books, 2005, pp. 5–89.
34.
EnglegauGKaranAMahalA. The economic impact of non-communicable diseases on households in India. Global Health2012; 8: e9–e9.
35.
Van DoorslaerEO’DonnellORannan-EliyaRP. Effect of payments for healthcare on poverty estimates in 11 countries in Asia: An analysis of household survey data. Lancet2006; 368: 1357–1364.
36.
KrishnaA. One illness away: Why people become poor and how they escape poverty, Oxford: Oxford University Press, 2010, pp. 1–69.
37.
KaplanGAKeilJE. Socioeconomic factors and cardiovascular disease: A review of the literature. Circulation1993; 88: 1973–1998.
38.
BhagwatiJPanagariyaA. India’s tryst with destiny: Debunking myths that undermine progress and addressing new challenges, Noida, India: Collins Business, 2012, pp. 202–229.
39.
DrezeJSenA. An uncertain glory: India and its contradictions, London: Allen Lane, 2013, pp. 143–181.
40.
ReddyKSPatelVJhaP. Lancet India Action Group for Universal Healthcare. Towards achievement of universal healthcare in India by 2020: A call to action. Lancet2011; 377: 760–768.
41.
GuptaRGupthaSJoshiR. Translating evidence into policy for cardiovascular disease control in India. Health Res Policy Systems2011; 9: e8–e8.
42.
MontalescotGSechtemUAchenbachS. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force of the Management of Stable Coronary Artery Disease of the European Society of Cardiology. Eur Heart J2013; 34: 2949–3003.
43.
LafeberMSpieringWSinghK. (on behalf of the SPACE collaboration). The cardiovascular polypill in high-risk patients. Eur J Prev Cardiol2011; 19: 1234–1242.
